Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients (TOMDF)

 Enrollment now paused in the randomized, double blind, placebo controlled clinical trial in severe and critical hospitalized COVID-19 patients to

Read more

Todos Medical Provides Update on COVID-19 Oral Antiviral 3CL Protease (Main Protease) Inhibitor Tollovir Clinical Development Program in Light of Molnupiravir Clinical Trial Data from Merck (TOMDF)

New York, NY, and Tel Aviv, ISRAEL, Oct. 04, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical, Ltd. (“Todos Medical”) (OTCQB:

Read more